Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate CING , were recently guests on Benzinga's All Access. Cingulate is a biotechnology company developing drugs for a range of underserved conditions.
The company has developed a proprietary technology called Precision Timed ReleaseTM (PTRTM). The technology allows a single pill to contain multiple doses of a drug, relieving the pill burden many people with chronic conditions suffer. Cingulate was just given clearance by the FDA to seek full approval for its lead candidate, CTx-1301.
Watch the full interview here: Featured photo by Hal Gatewood on Unsplash . This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
.
